Ask AI
Treating HER2 Positive BC With Brain Mets

CE / CME

Interactive Case Challenge: Treatment of HER2-Positive Breast Cancer With Brain Metastases

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

European Learners: 0.50 EBAC® CE Credit

Released: February 05, 2026

Expiration: August 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For a patient with hormone receptor (HR)-negative/HER2-positive metastatic breast cancer (MBC) with no evidence of progression after 4-8 cycles with first-line trastuzumab/pertuzumab/taxane (THP), a switch to maintenance therapy with which of the following agents added to trastuzumab plus pertuzumab significantly improved progression-free survival (PFS) compared with trastuzumab plus pertuzumab in a phase III study?

2.

As of December 2025, which of the following was approved by the FDA for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer?